1126367-88-1

Basic information

• Product Name: 5-bromo-4-chloro-2-methylaniline
• Synonyms: 5-bromo-4-chloro-2-methylaniline;BenzenaMine, 5-broMo-4-chloro-2-Methyl-;5-bromo-4-chloro-2-methylbenzenamine;5-Bromo-4-chloro-2-methyl-phenylamine
• CAS NO: 1126367-88-1
• Molecular Formula: C₇H₇BrClN
• Molecular Weight: 220.49418
• EINECS: 604-604-1
• Mol File: 1126367-88-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 5-bromo-4-chloro-2-methylaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-4-chloro-2-methylaniline(1126367-88-1)
• EPA Substance Registry System: 5-bromo-4-chloro-2-methylaniline(1126367-88-1)

Safety Data

• Hazardous Substances Data: 1126367-88-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-bromo-4-chloro-2-methylaniline is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with specific therapeutic properties.
Used in Dye Industry:
In the dye industry, 5-bromo-4-chloro-2-methylaniline is used as an intermediate to produce a range of dyes, leveraging its chemical structure to create compounds with desired color characteristics.
Used in Agrochemical Industry:
5-bromo-4-chloro-2-methylaniline is utilized as an intermediate in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural chemicals to protect crops.
Used in Organic Synthesis:
As a building block in organic synthesis, 5-bromo-4-chloro-2-methylaniline is used to construct more complex organic molecules, facilitating the creation of a variety of chemical compounds for different applications.
Used in Chemical Reactions as a Reagent:
5-bromo-4-chloro-2-methylaniline serves as a reagent in various chemical reactions, playing a crucial role in the synthesis process and aiding in the formation of desired products.

Upstream product

• 6627-51-6 1-bromo-2-chloro-4-methylbenzene 
• 1126367-34-7 1-bromo-2-chloro-4-methyl-5-nitrobenzene 

Downstream Products

• 1126369-57-0 N-(5-bromo-4-chloro-2-methylphenyl)-4-(pyridin-2-ylmethoxy)benzamide 
• 1126367-36-9 N-(4-chloro-2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-4-(pyridin-2-ylmethoxy)benzamide 
• 1126368-33-9 N-[4-chloro-5-(1H-imidazol-2-yl)-2-methylphenyl]-4-(pyridin-2-ylmethoxy)benzamide 
• 1126366-38-8 N-[4-chloro-2-methyl-5-(1-methyl-1H-imidazol-4-yl)phenyl]-4-(pyridin-2-ylmethoxy)benzamide 
• 1126368-35-1 N-[4-chloro-5-(1,2-dimethyl-1H-imidazol-4-yl)-2-methylphenyl]-4-(pyridin-2-ylmethoxy)benzamide 
• 1126368-31-7 N-[4-chloro-2-methyl-5-(1-methyl-1H-imidazol-2-yl)phenyl]-4-(pyridin-2-ylmethoxy)benzamide 

Relevant articles and documents

N-HETEROARYL INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF

The present invention is directed to substituted certain N-heteroaryl indazole derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.

Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254)

Aberrant hedgehog (Hh) pathway signaling is implicated in multiple cancer types and targeting the Smoothened (SMO) receptor, a key protein of the Hh pathway, has proven effective in treating metastasized basal cell carcinoma. Our lead optimization effort focused on a series of heteroarylamides. We observed that a methyl substitution ortho to the heteroaryl groups on an aniline core significantly improved the potency of this series of compounds. These findings predated the availability of SMO crystal structure in 2013. Here we retrospectively applied quantum mechanics calculations to demonstrate the o-Me substitution favors the bioactive conformation by inducing a dihedral twist between the heteroaryl rings and the core aniline. The o-Me also makes favorable hydrophobic interactions with key residue side chains in the binding pocket. From this effort, two compounds (AZD8542 and AZD7254) showed excellent pharmacokinetics across multiple preclinical species and demonstrated in vivo activity in abrogating the Hh paracrine pathway as well as anti- tumor effects.

HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS

The present disclosure relates to heterocyclic amide compounds, which are useful for inhibiting the Hedgehog pathway, and their use in treating a disease or medical condition mediated alone or in part by Hedgehog pathway inhibition. Also disclosed are methods for manufacture of these compounds, pharmaceutical compositions including these compounds, and use of these compounds in the manufacture of medicaments for treating such diseases and medical conditions in a subject. Formula (IA) with the provisio that either R2or R3 is (Z).